Integrated DNA Technologies

Integrated DNA Technologies Unveils New Custom Vector Onboarding Tool to Optimize Gene Synthesis

Retrieved on: 
Wednesday, March 27, 2024
Genomics, Gene, Synthetic biology, Integration, IDT, Research, DNA, Confidentiality, IP, Integrated DNA Technologies

CORALVILLE, Iowa, March 27, 2024 /PRNewswire/ --Global genomics solutions provider Integrated DNA Technologies (IDT) is expanding its gene synthesis offerings with a new custom vector onboarding tool. The easy-to-use solution is designed for researchers who want to skip in-house cloning steps and move quickly into functional studies with 100% sequence-verified clonal DNA. By using IDT's new gene synthesis custom vector onboarding tool, researchers can submit their vector sequence via IDT's website without having to contact a sales representative, eliminating unnecessary back-and-forth emails.

Key Points: 
  • CORALVILLE, Iowa, March 27, 2024 /PRNewswire/ --Global genomics solutions provider Integrated DNA Technologies (IDT) is expanding its gene synthesis offerings with a new custom vector onboarding tool.
  • By using IDT's new gene synthesis custom vector onboarding tool, researchers can submit their vector sequence via IDT's website without having to contact a sales representative, eliminating unnecessary back-and-forth emails.
  • To see IDT's new custom vector onboarding tool, visit https://www.idtdna.com/genes .
  • IDT's new custom onboarding vector tool is the latest addition to IDT's broad synthetic biology portfolio, which is comprised of gene and gene fragment offerings.

Volta Labs and Integrated DNA Technologies Partner to Advance Target Enrichment Workflows

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Agitation, Workflow, IDT, Integrated DNA Technologies, Genomics, Learning, NGS, Library, Callisto, Integration, Fine chemical

Volta Labs and IDT are working to create platform-agnostic solutions, with the goal of walk-away sample prep, starting with target enrichment workflows.

Key Points: 
  • Volta Labs and IDT are working to create platform-agnostic solutions, with the goal of walk-away sample prep, starting with target enrichment workflows.
  • Initial study shows capture metrics and variant calling results were comparable or better for libraries processed using the Volta Labs benchtop instrument.
  • "We look forward to working closely with Volta to advance sample prep approaches and enable higher quality sequencing metrics which are especially important in target enrichment workflows like oncology applications."
  • "IDT is focused on optimizing tools and solutions that enable a higher degree of NGS performance," said Udayan Umapathi, CEO at Volta Labs.

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Retrieved on: 
Tuesday, January 9, 2024
University, Patient, IEI, Research, DHR, Collection, Health, IDT, RNA, IGI, Science, Tissue, Nobel, Translation, Medicine, University of California, Berkeley, Government, Danaher Corporation, Beacon, Public, Safety, Quality control, FDA, Leica Biosystems, DSM-IV codes, Immunity, Engineering, Leica Microsystems, Brain, Hemophagocytic lymphohistiocytosis, Gene editing, Integrated DNA Technologies, HLH, Medical device

The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.

Key Points: 
  • The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.
  • The collaboration, which enables a substantial new research program at IGI, is the largest Danaher Beacon to date.
  • The Beacons program funds pioneering academic research with the goal of developing innovative technologies and applications for human health.
  • The unique nature of CRISPR makes it ideal for developing and deploying a platform capability for CRISPR cures on demand.

Scrum Studio and Hakuhodo Launch AgeTechX to Redefine the Future of Health and Longevity

Retrieved on: 
Friday, December 1, 2023
World Health Organization, DNA, SAN, Ageing, Integrated DNA Technologies, Partnership, Thought, Hakuhodo

SAN FRANCISCO, Dec. 1, 2023 /PRNewswire/ -- Scrum Studio Inc., in partnership with Hakuhodo, announces the launch of AgeTechX, a visionary open innovation program dedicated to helping scale and grow startups developing products and solutions working to revolutionize the $2 trillion field of aging-related technology and services by collaborating with Japanese corporations.

Key Points: 
  • Moreover, the number of individuals aged 80 or older is projected to triple by 2050, reaching a staggering 426 million.
  • This demographic transformation presents an enormous opportunity for startups to pioneer innovative solutions catering to this growing aging population.
  • "In a world where the aging population is on the rise, we started AgeTechX to encourage innovation, uniting startups and industry pioneers to shape the future of aging-related technology and services, " said Yuya Watanabe, Program Associate with Scrum Studio.
  • AgeTechX aims to create businesses that solve the problems of Japan's aging society together with startups from around the world that have new ideas and technologies.

Complete Genomics opens $3.2 million manufacturing facility at its San Jose headquarters

Retrieved on: 
Thursday, November 16, 2023
Foot, International Organization (journal), WGS, Research, SAN, Engineering, Entrepreneurship, Integrated DNA Technologies, Completeness, Base pair, ISO, Complete Genomics, Genomics, Integration, Biotechnology

SAN JOSE, Calif., Nov. 16, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced plans for the opening of a $3.2 million manufacturing facility within its headquarters in San Jose, California.

Key Points: 
  • SAN JOSE, Calif., Nov. 16, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced plans for the opening of a $3.2 million manufacturing facility within its headquarters in San Jose, California.
  • The facility, scheduled to open in March 2024, will give Complete Genomics customers access to a U.S.-based supply chain translating into faster delivery times for its next generation sequencing products.
  • The new facility will house Complete Genomics' research and development, engineering and ISO (International Organization for Standardization) manufacturing operations.
  • In May 2017, Complete Genomics moved to its current 78,979 square foot location in San Jose, which also includes a warehousing facility.

Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market

Retrieved on: 
Wednesday, November 1, 2023
Cloning, Growth, Integrated DNA Technologies, Recombinant, Pet industry

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The "Recombinant DNA Technology: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The "Recombinant DNA Technology: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Recombinant DNA Technology estimated at US$64.7 Billion in the year 2022, is projected to reach a revised size of US$93.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2022-2030.
  • Medical, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$70.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 4.4% CAGR
    The Recombinant DNA Technology market in the U.S. is estimated at US$18.9 Billion in the year 2022.

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
Tuesday, October 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

Complete Genomics Partners with Integrated DNA Technologies to Establish New Ecosystem of NGS Products

Retrieved on: 
Wednesday, October 18, 2023
Linda, Complete Genomics, Laboratory, Genomics, IDT, Infection, RNA interference, RNA, CRISPR, PCR, Research, Learning, MGI, NGS, Commercial, Ecosystem, Partnership, Workflow, Integrated DNA Technologies, Synthetic biology, Integration, Marketing, SAN, Completeness, Antibiotics

SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics' innovative DNBSEQ™ sequencing platforms.

Key Points: 
  • SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics' innovative DNBSEQ™ sequencing platforms.
  • Its relationship with MGI, parent company of Complete Genomics, started in June 2018.
  • With Complete Genomics' technical support, IDT has empowered users in library preparation through conversion workflow and data generated by targeted sequencing.
  • With an increasing installation base of DNBSEQ sequencing platforms, the companies are enhancing their partnership by optimizing IDT's technology for Complete Genomics' sequencing platforms.

Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine

Retrieved on: 
Tuesday, October 17, 2023
Science, Other Science, Biotechnology, Research, Health, Genetics, Clinical Trials, Other Health, Investment, Multimedia, DHR, Danaher Corporation, NYSE, ICH, Cas12a, Biology, Static pressure, Genome, Therapy, Integrated DNA Technologies, Temperature, ISO, CGMP, RUO, Humidity, ISO 8, Ultra, Documentation, Oligonucleotide, IDT, Drug discovery, Integration, RNA, Genomics, Danaher, HDR, Fine chemical, Medical device, CRISPR

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.

Key Points: 
  • Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
  • These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
  • As a pioneer in genome editing, IDT’s continued investments will enable customers to rapidly move from clinical development to commercialization.
  • Mortenson Company, a team led by OPN Architects and Barr Engineering Co. on the facility design and construction of its cGMP facility.

Integrated DNA Technologies Reveals Launch of xGen™ Products for Ultima Genomics®

Retrieved on: 
Wednesday, September 27, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, Learning, DNA, XGen Studios, Genomics, NGS, Integrated DNA Technologies, Ligation, Multimedia, RNA, Manager, Chemistry, IDT, Ultima, WGS, Small Business Saturday, Integration, PCR, Fine chemical, Antibiotics, Birth control, Paint

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.

Key Points: 
  • With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announces the availability of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform.
  • The products are designed to minimize sequence errors from PCR or sequencing that might impact demultiplexing.
  • xGen HybCap Adapters for Ultima Genomics—full-length adapters for library construction prior to hybridization capture, using TA-ligation workflows for incorporating sample indexing during the ligation step.
  • xGen HybCap Lib Amp Primers for Ultima Genomics—premixed PCR primers used to increase yield for sequencing libraries post-hybridization capture.